
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals Inc. has demonstrated strong financial performance with Livmarli's net sales revenue reaching $64.1 million in Q4 2024, reflecting an 8.4% increase from Q3 2024 and a significant 54.5% growth compared to Q4 2023. The company anticipates continued revenue growth in 2025, particularly from Livmarli's progressive familial intrahepatic cholestasis indication, alongside positive developments in its other product lines, including volixibat and its bile acid product portfolio. Additionally, Mirum is positioned as a cash-flow positive commercial-stage entity, with multiple clinical milestones that present further upside potential, reinforcing a favorable outlook for future performance.
Bears say
Mirum Pharmaceuticals faces several significant risks that contribute to a negative outlook for its stock, including the possibility of sales growth for its products, LIVMARLI and volixibat, falling short of expectations and the potential for regulatory setbacks. The company reported a net loss of $87.9 million for FY2024, driven by high research and development, and selling, general and administrative expenses, which may hinder its ability to fund operations and necessitate additional capital raises with possible share dilution. Furthermore, the company must demonstrate differentiation within its pipeline to ensure commercial uptake, as failure to do so, combined with uncertainties surrounding clinical trial outcomes and safety issues, could jeopardize future profitability.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares